Home | Welcome to Contract Pharma   
Last Updated Monday, May 4 2015

Print

Breaking News

Related Searches: Development Manufacturing Phase II API
March 15, 2012
MAKScientific eligible to receive as much as $34 million  Read More »
March 15, 2012
Gains Phase II Iron Chelator Treatment  Read More »
March 15, 2012
Moskowitz to lead the strategic direction of financial and capital markets activities  Read More »
March 15, 2012
Needleman responsible for all day-to-day operations  Read More »
March 14, 2012
Will complete full commercial manufacture of DuoCort’s Plenadren  Read More »
March 14, 2012
To find compounds against respiratory and inflammatory targets   Read More »
March 14, 2012
Will develop a generic copy for small-scale production  Read More »
March 14, 2012
Vaillant, Ernst and McDonnell join finance, operations and business development   Read More »
March 13, 2012
Will provide commercial manufacture of talactoferrin   Read More »
March 13, 2012
All rights licensed to Pfizer will revert to Biocon  Read More »
March 13, 2012
Adds instrumentation and increased analytical capabilities  Read More »
March 13, 2012
Offers enhanced new language capabilities and data integration  Read More »
March 13, 2012
Adds 12,000 sq.-ft. of space for validation, packaging testing  Read More »
March 13, 2012
Vermass to lead manufacturing operations  Read More »
March 12, 2012
Trochu responsible for driving sales force excellence  Read More »



Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On